LONDON, July 23, 2014 /PRNewswire/ --
On Tuesday, July 22, 2014, the NASDAQ Composite ended at 4,456.02, up 0.71%, the Dow Jones Industrial Average finished the day 0.36% higher at 17,113.54, and the S&P 500 closed at 1,983.53, up 0.50%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 713.75, up 0.83%, with the index also advancing 5.99% in the previous three months. Investor-Edge has initiated coverage on the following equities: ImmunoCellular Therapeutics Ltd (NYSE MKT: IMUC), Aeterna Zentaris Inc. (NASDAQ: AEZS), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), BioDelivery Sciences International Inc. (NASDAQ: BDSI), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free research on these five companies can be accessed at:
http://investor-edge.com/register
ImmunoCellular Therapeutics Ltd's stock finished Tuesday's session 3.07% higher at $0.93. A total of 0.45 million shares were traded, which was below its three months average volume of 0.79 million shares. The stock moved between $0.89 and $0.95 during the session. Over the last three trading sessions and the previous one month, ImmunoCellular Therapeutics Ltd's shares have declined 1.17% and 21.19%, respectively. However from the beginning of 2014, the stock has gained 0.54%. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $1.56 is greater than its 50-day moving average of $1.16. ImmunoCellular Therapeutics Ltd's shares have a Relative Strength Index (RSI) of 23.78. Sign up and read the free notes on IMUC at:
http://www.Investor-Edge.com/IMUC-23Jul2014
On Tuesday, shares in Aeterna Zentaris Inc. fluctuated between $1.20 and $1.23 before ending the session 1.64% lower at $1.20. The company reported a trading volume of 0.81 million shares, above its three months average volume of 0.62 million shares. Aeterna Zentaris Inc.'s shares have advanced 8.11% in the last one month and 2.56% in the previous three months. However, the stock lost 13.04%, since the start of this year. The stock is trading above its 50-day moving average of $1.13. Moreover, shares of the company have an RSI of 56.43. The complimentary notes on AEZS can be downloaded as in PDF format at:
http://www.Investor-Edge.com/AEZS-23Jul2014
On Tuesday, Lexicon Pharmaceuticals Inc.'s stock finished the day at its previous day's closing price of $1.54. The company recorded a trading volume of 0.55 million shares, much below its three months average volume of 1.44 million shares. The stock oscillated between $1.52 and $1.58 during the session. Although, Lexicon Pharmaceuticals Inc.'s shares have gained 8.45% in the previous three trading sessions, it has declined, 7.23% in the last one month and 14.40% on YTD basis. The stock is trading above its 50-day moving average of $1.53, while the 50-day moving average is below Lexicon Pharmaceuticals Inc.'s 200-day moving average of $1.85. Additionally, the company's stock has an RSI of 46.76. Register for free on Investor-Edge and access the latest research on LXRX at:
http://www.Investor-Edge.com/LXRX-23Jul2014
On Tuesday, shares in BioDelivery Sciences International Inc. recorded a trading volume of 0.44 million shares, lower than its three months average volume of 0.96 million shares. The stock ended the day at $12.75, which was 1.27% above its previous day's closing of $12.59, and registered an intraday range of $12.65 and $12.95. Over the last three trading sessions and over the past three months, BioDelivery Sciences International Inc.'s shares have gained 2.08% and 50.53%, respectively. Further, the stock has surged 116.47% since the start of this year. The company's stock is trading above its 50-day and 200-day moving averages of $11.11 and $7.95, respectively. Furthermore, shares of the company have an RSI of 52.39. The complete research on BDSI is available for free at:
http://www.Investor-Edge.com/BDSI-23Jul2014
Jazz Pharmaceuticals PLC's stock finished the Tuesday's session 0.23% lower at $145.87. A total of 0.51 million shares were traded, which was below its three months average volume of 0.83 million shares. The stock moved between $145.48 and $149.37 during the session. Over the last three trading sessions and the previous three months, Jazz Pharmaceuticals PLC's shares have gained 2.98% and 0.36%, respectively. Additionally, from the beginning of 2014, the company's stock has gained an upside of 15.26%. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $143.96 is greater than its 200-day moving average of $132.41. Jazz Pharmaceuticals PLC's stock traded at a PE ratio of 79.65 and has an RSI of 47.21. Free in depth research on JAZZ is available at:
http://www.Investor-Edge.com/JAZZ-23Jul2014
About Investor-Edge.com
At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Investor-Edge
